studies have shown that inhibition of polo-like-kinases can lead to tumor cell death , including a phase 2 study in aml where response rates with a prior plk inhibitor of up to 31 % were observed when used in conjunction with a standard therapy for aml ( low-dose cytarabine ( “ ldac ” ) ) versus a 13.3 % response rate with ldac alone . we believe the more selective nature of onvansertib to plk1 , its 24-hour half-life and oral bioavailability , as well as its demonstrated safety and tolerability , with expected on-target , easy to manage and reversible side effects , may prove useful in addressing clinical therapeutic needs across a variety of cancers . onvansertib has been tested in-vivo in different xenograft and transgenic models suggesting tumor growth inhibition or tumor regression when used in combination with other therapies . onvansertib has been tested for antiproliferative activity on a panel of 148 tumor cell lines and appeared highly active with an ic 50 ( a measure concentration for 50 % target inhibition ) below 100 nm in 75 cell lines and ic 50 values below 1 um in 133 out of 148 cell lines . onvansertib also appears active in cells expressing multi-drug resistant ( “ mdr ” ) transporter proteins and we believe its apparent ability to overcome the mdr transporter resistance mechanism in cancer cells could prove useful in broader drug combination applications . in in-vitro and in-vivo preclinical studies , synergy ( interaction of discrete drugs such that the total effect is greater than the sum of the individual effects ) has been demonstrated with onvansertib when used in combination with numerous different chemotherapies , including cisplatin , cytarabine , doxorubicin , gemcitabine and paclitaxel , as well as targeted therapeutics , such as abiraterone acetate ( zytiga ® ) , histone deacetylase ( “ hdac ” ) inhibitors , such as belinostat ( beleodaq ® ) , quizartinib ( ac220 ) , a development stage flt3 inhibitor , and bortezomib ( velcade ® ) . these therapies are used clinically for the treatment of leukemias , lymphomas and solid tumor cancers , including aml , non-hodgkin lymphoma ( “ nhl ” ) , mcrpc , mcrc , and triple negative breast cancer ( “ tnbc ” ) . we achieved a number of key milestones throughout 2019 and anticipate achieving additional milestones through the end of 2020 : phase 2 trial of onvansertib in combination with abiraterone acetate ( zytiga ® ) and prednisone for the treatment of metastatic castration-resistant prostate cancer initiated enrollment and evaluation of 3 safety lead-in patients in the second arm ( 2-week dosing schedule ) with onvansertib at 18 mg/m 2 in combination with abiraterone acetate ( zytiga ) and prednisone . provide safety and preliminary efficacy data of onvansertib in combination with abiraterone acetate ( zytiga ® ) and prednisone in patients treated through the end of 2019 and into 2020 . 40 presented data from the mcrpc trial at key oncology conferences throughout 2019 , including the asia-pacific prostate cancer conference ( `` appc `` ) , and first quarter of 2020 including asco-gu . phase 1b/2 trial of onvansertib in combination with folfiri and bevacizumab ( avastin ® ) for second-line treatment of metastatic colorectal cancer with a kras mutation completed enrollment and evaluation of the initial dose level cohort of onvansertib 12 mg/m 2 and fully enrolled the second dose level ( onvansertib 15 mg/m 2 ) cohort . presented data from the mcrc trial at key oncology conferences throughout 2019 , including the european society for medical oncology ( “ esmo ” ) , and first quarter of 2020 including asco-gi . phase 1b/2 trial of onvansertib in combination with either low-dose cytarabine or decitabine for the treatment of acute myeloid leukemia completed phase 1b dose escalation safety segment of trial , identified the recommended phase 2 dose ( “ rp2d ” ) of onvansertib at 60mg/m 2 . initiated the phase 2 segment of the aml trial , which will enroll approximately 32 patients , for continued evaluation of safety and efficacy of onvansertib in combination with decitabine . presented data from the aml trial at key oncology conferences , including the european society for medical oncology ( `` esmo `` ) and the american society of hematology ( “ ash ” ) annual meetings . during 2019 , we advanced our business with the following activities : announced positive data presented in an oral session at the american society of hematology ( “ ash ” ) conference response to treatment in patients with acute myeloid leukemia . on december 9 , 2019 , we announced the presentation of data demonstrating efficacy , durability of response and safety of onvansertib from the completed phase 1b segment of the ongoing trial in acute myeloid leukemia , in an oral session at ash . efficacy was observed in patients treated at onvansertib doses ranging from 27 to 90 mg/m 2 , with a complete response ( cr ) and cr with incomplete count recovery ( cri ) rate of 31 % ( 5 out of 16 patients ) . treatment was well tolerated ; adverse events related to onvansertib were primarily on-target hematological ( based on mechanism of action ) and were easily managed and reversible . biomarker positive patients showed a higher response to treatment ; 67 % ( 4 out of 6 ) patients had marked decreases in bone marrow blast cells vs only 18 % ( 1 out of 11 ) biomarker negative patients . announced data showing the ability of onvanserib to rescue patients previously treated with , and resistant to , venetoclax in acute myeloid leukemia . on december 4 , 2019 , we announced data showing the ability of onvansertib to rescue venetoclax-resistant aml patients . story_separator_special_tag the decrease in value was recorded as non-operating gain for the year ended december 31 , 2019 . net loss net loss and per share amounts were as follows : replace_table_token_3_th the $ 2,548,283 decrease in net loss attributable to common shareholders was primarily the result of a decrease in series b deemed dividend expense of $ 2,769,533 , and a decrease in operating expenses of $ 508,611 offset by a decrease in gain from change in fair value of derivative financial instruments-warrants of $ 588,884 for the for the year ended december 31 , 2019 as compared to the same period of 2018. the $ 5.46 decrease in basic and diluted net loss per share was impacted by the decrease in net loss attributable to shareholders and the increase in basic weighted average shares outstanding resulting primarily from the sales of approximately 3.9 million shares of common stock and common stock equivalents through public and direct offerings , issuance of approximately 0.5 million shares of common stock upon exercise of warrants , and 0.3 million shares of common stock upon conversion of series c convertible preferred stock . 46 liquidity and capital resources as of december 31 , 2019 , we had $ 10,195,292 in cash and cash equivalents . net cash used in operating activities for the year ended december 31 , 2019 was $ 13,267,500 , compared to $ 13,199,013 for the year ended december 31 , 2018 . our use of cash was primarily a result of the net loss of $ 16,414,159 for the year ended december 31 , 2019 , adjusted for items mainly related to stock-based compensation of $ 884,943 , release of clinical trial funding commitment of $ 703,327 , and depreciation and amortization of $ 494,232 . the changes in our operating assets and liabilities consisted primarily of higher accounts payable and accrued expenses . at our current and anticipated levels of operating losses , we expect to continue to incur an operating cash outflow for the next several years . as of december 31 , 2019 and 2018 , we had working capital of $ 6,571,985 and $ 9,841,947 , respectively . the decrease in working capital is primarily due to the decrease in cash and cash equivalents and an increase in accrued liabilities . net cash ( used ) /provided by investing activities was $ ( 67,622 ) and $ 22,842 for the years ended december 31 , 2019 and 2018 , respectively . investing activities during the year ended december 31 , 2019 consisted primarily of the purchase of capital equipment of $ 67,622 , while investing activities during the year ended december 31 , 2018 consisted primarily of cash provided by disposal of capital equipment of $ 27,942 . story_separator_special_tag style= `` line-height:120 % ; text-indent:48px ; font-size:10pt ; `` > on may 10 , 2019 , we entered into a securities purchase agreement with lpc , gross proceeds were approximately $ 1.5 million . the may 2019 securities purchase agreement consisted of ( i ) 458,015 shares of common stock ( including pre-funded warrants ) at a purchase price of $ 3.275 per share and ( ii ) 458,015 series d warrants with an exercise price of $ 3.15 per share , expiring on november 12 , 2024. none of the series d warrants have been exercised as of february 20 , 2020. on august 20 , 2019 , we entered into a securities purchase agreement with lpc , gross proceeds were approximately $ 1.5 million . the august 2019 securities purchase agreement consisted of ( i ) 727,802 shares of common stock ( including pre-funded warrants ) at a purchase price of $ 2.061 per share and ( ii ) 727,802 series f warrants with an exercise price of $ 1.936 per share , expiring on february 24 , 2025. none of the series f warrants have been exercised as of february 20 , 2020. on october 30 , 2019 , we closed a private placement with certain institutional investors for gross proceeds of approximately $ 5.0 million . we sold an aggregate of ( i ) 2,756,340 shares of common stock ( including pre-funded warrants ) at a purchase price of $ 1.814 per share , ( ii ) 2,756,340 series g warrants with an exercise price of $ 1.56 per share , expiring on april 30 , 2025 , ( iii ) 2,756,340 series h warrants with an exercise price of $ 1.56 per share , expiring on april 30 , 2021 , and ( iv ) 206,726 placement agent warrants at an exercise price of $ 2.2675 per share , expiring on april 30 , 2025. none of the series g or placement agent warrants have been exercised as of february 20 , 2020. we received net proceeds of approximately $ 1.5 million from the exercise of 1,005,072 series h warrants on january 27 , 2020. nasdaq notice on september 5 , 2017 , we received a written notice from nasdaq notifying us that we were not in compliance with nasdaq listing rule 5550 ( a ) ( 2 ) for continued listing on the nasdaq capital market , as the minimum bid price of our common stock had been below $ 1.00 per share for 30 consecutive business days . the notice had no immediate effect on the listing of our common stock , and our common stock continued to trade on the nasdaq capital market under the symbol “ trov ” . in accordance with nasdaq listing rule 5810 ( c ) ( 3 ) ( a ) , we had until march 5 , 2018 , to regain compliance with the minimum bid price requirement . on march 6 , 2018 , nasdaq informed us that we were eligible for an additional 180 calendar day period until september 4 , 2018 to regain compliance with the minimum $ 1.00 bid price per share requirement . to regain compliance ,

net cash provided by financing activities was $ 12,077,281 during the year ended december 31 , 2019 , compared to $ 16,403,540 provided in financing activities during the year ended december 31 , 2018 . financing activities during the year ended december 31 , 2019 related primarily to sales of common stock , warrants and proceeds from exercise of warrants . financing activities during the year ended december 31 , 2018 related primarily to sales of common stock and series b convertible preferred stock and proceeds from exercise of warrants , offset by the pay-off of our equipment line of credit . based on our current business plan and assumptions , we expect to continue to incur significant losses and require significant additional capital to further advance our clinical trial programs and support our other operations . considering our current cash resources , we believe our existing resources will be sufficient to fund our planned operations into third quarter of 2020. in addition , we have based our cash sufficiency estimates on our current business plan and assumptions that may prove to be wrong . we could utilize our available capital resources sooner than we currently expect , and we could need additional funding to sustain our operations even sooner than currently anticipated . these circumstances raise substantial doubt about our ability to continue as a going concern . our working capital requirements will depend upon numerous factors including but not limited to the nature , cost and timing of our research and development programs . to date , our sources of cash have been primarily limited to the sale of equity securities . we can not be certain that additional funding will be available on acceptable terms , or at all . to the extent that we raise additional funds by issuing equity securities , our stockholders may experience significant dilution . if we are unable to raise additional capital when required or on acceptable terms , we may have to significantly delay , scale back or discontinue the development and or commercialization of one or more product candidates , all of which may have a material adverse impact on our operations .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```net cash provided by financing activities was $ 12,077,281 during the year ended december 31 , 2019 , compared to $ 16,403,540 provided in financing activities during the year ended december 31 , 2018 . financing activities during the year ended december 31 , 2019 related primarily to sales of common stock , warrants and proceeds from exercise of warrants . financing activities during the year ended december 31 , 2018 related primarily to sales of common stock and series b convertible preferred stock and proceeds from exercise of warrants , offset by the pay-off of our equipment line of credit . based on our current business plan and assumptions , we expect to continue to incur significant losses and require significant additional capital to further advance our clinical trial programs and support our other operations . considering our current cash resources , we believe our existing resources will be sufficient to fund our planned operations into third quarter of 2020. in addition , we have based our cash sufficiency estimates on our current business plan and assumptions that may prove to be wrong . we could utilize our available capital resources sooner than we currently expect , and we could need additional funding to sustain our operations even sooner than currently anticipated . these circumstances raise substantial doubt about our ability to continue as a going concern . our working capital requirements will depend upon numerous factors including but not limited to the nature , cost and timing of our research and development programs . to date , our sources of cash have been primarily limited to the sale of equity securities . we can not be certain that additional funding will be available on acceptable terms , or at all . to the extent that we raise additional funds by issuing equity securities , our stockholders may experience significant dilution . if we are unable to raise additional capital when required or on acceptable terms , we may have to significantly delay , scale back or discontinue the development and or commercialization of one or more product candidates , all of which may have a material adverse impact on our operations .
```    
 Suspicious Activity Report : studies have shown that inhibition of polo-like-kinases can lead to tumor cell death , including a phase 2 study in aml where response rates with a prior plk inhibitor of up to 31 % were observed when used in conjunction with a standard therapy for aml ( low-dose cytarabine ( “ ldac ” ) ) versus a 13.3 % response rate with ldac alone . we believe the more selective nature of onvansertib to plk1 , its 24-hour half-life and oral bioavailability , as well as its demonstrated safety and tolerability , with expected on-target , easy to manage and reversible side effects , may prove useful in addressing clinical therapeutic needs across a variety of cancers . onvansertib has been tested in-vivo in different xenograft and transgenic models suggesting tumor growth inhibition or tumor regression when used in combination with other therapies . onvansertib has been tested for antiproliferative activity on a panel of 148 tumor cell lines and appeared highly active with an ic 50 ( a measure concentration for 50 % target inhibition ) below 100 nm in 75 cell lines and ic 50 values below 1 um in 133 out of 148 cell lines . onvansertib also appears active in cells expressing multi-drug resistant ( “ mdr ” ) transporter proteins and we believe its apparent ability to overcome the mdr transporter resistance mechanism in cancer cells could prove useful in broader drug combination applications . in in-vitro and in-vivo preclinical studies , synergy ( interaction of discrete drugs such that the total effect is greater than the sum of the individual effects ) has been demonstrated with onvansertib when used in combination with numerous different chemotherapies , including cisplatin , cytarabine , doxorubicin , gemcitabine and paclitaxel , as well as targeted therapeutics , such as abiraterone acetate ( zytiga ® ) , histone deacetylase ( “ hdac ” ) inhibitors , such as belinostat ( beleodaq ® ) , quizartinib ( ac220 ) , a development stage flt3 inhibitor , and bortezomib ( velcade ® ) . these therapies are used clinically for the treatment of leukemias , lymphomas and solid tumor cancers , including aml , non-hodgkin lymphoma ( “ nhl ” ) , mcrpc , mcrc , and triple negative breast cancer ( “ tnbc ” ) . we achieved a number of key milestones throughout 2019 and anticipate achieving additional milestones through the end of 2020 : phase 2 trial of onvansertib in combination with abiraterone acetate ( zytiga ® ) and prednisone for the treatment of metastatic castration-resistant prostate cancer initiated enrollment and evaluation of 3 safety lead-in patients in the second arm ( 2-week dosing schedule ) with onvansertib at 18 mg/m 2 in combination with abiraterone acetate ( zytiga ) and prednisone . provide safety and preliminary efficacy data of onvansertib in combination with abiraterone acetate ( zytiga ® ) and prednisone in patients treated through the end of 2019 and into 2020 . 40 presented data from the mcrpc trial at key oncology conferences throughout 2019 , including the asia-pacific prostate cancer conference ( `` appc `` ) , and first quarter of 2020 including asco-gu . phase 1b/2 trial of onvansertib in combination with folfiri and bevacizumab ( avastin ® ) for second-line treatment of metastatic colorectal cancer with a kras mutation completed enrollment and evaluation of the initial dose level cohort of onvansertib 12 mg/m 2 and fully enrolled the second dose level ( onvansertib 15 mg/m 2 ) cohort . presented data from the mcrc trial at key oncology conferences throughout 2019 , including the european society for medical oncology ( “ esmo ” ) , and first quarter of 2020 including asco-gi . phase 1b/2 trial of onvansertib in combination with either low-dose cytarabine or decitabine for the treatment of acute myeloid leukemia completed phase 1b dose escalation safety segment of trial , identified the recommended phase 2 dose ( “ rp2d ” ) of onvansertib at 60mg/m 2 . initiated the phase 2 segment of the aml trial , which will enroll approximately 32 patients , for continued evaluation of safety and efficacy of onvansertib in combination with decitabine . presented data from the aml trial at key oncology conferences , including the european society for medical oncology ( `` esmo `` ) and the american society of hematology ( “ ash ” ) annual meetings . during 2019 , we advanced our business with the following activities : announced positive data presented in an oral session at the american society of hematology ( “ ash ” ) conference response to treatment in patients with acute myeloid leukemia . on december 9 , 2019 , we announced the presentation of data demonstrating efficacy , durability of response and safety of onvansertib from the completed phase 1b segment of the ongoing trial in acute myeloid leukemia , in an oral session at ash . efficacy was observed in patients treated at onvansertib doses ranging from 27 to 90 mg/m 2 , with a complete response ( cr ) and cr with incomplete count recovery ( cri ) rate of 31 % ( 5 out of 16 patients ) . treatment was well tolerated ; adverse events related to onvansertib were primarily on-target hematological ( based on mechanism of action ) and were easily managed and reversible . biomarker positive patients showed a higher response to treatment ; 67 % ( 4 out of 6 ) patients had marked decreases in bone marrow blast cells vs only 18 % ( 1 out of 11 ) biomarker negative patients . announced data showing the ability of onvanserib to rescue patients previously treated with , and resistant to , venetoclax in acute myeloid leukemia . on december 4 , 2019 , we announced data showing the ability of onvansertib to rescue venetoclax-resistant aml patients . story_separator_special_tag the decrease in value was recorded as non-operating gain for the year ended december 31 , 2019 . net loss net loss and per share amounts were as follows : replace_table_token_3_th the $ 2,548,283 decrease in net loss attributable to common shareholders was primarily the result of a decrease in series b deemed dividend expense of $ 2,769,533 , and a decrease in operating expenses of $ 508,611 offset by a decrease in gain from change in fair value of derivative financial instruments-warrants of $ 588,884 for the for the year ended december 31 , 2019 as compared to the same period of 2018. the $ 5.46 decrease in basic and diluted net loss per share was impacted by the decrease in net loss attributable to shareholders and the increase in basic weighted average shares outstanding resulting primarily from the sales of approximately 3.9 million shares of common stock and common stock equivalents through public and direct offerings , issuance of approximately 0.5 million shares of common stock upon exercise of warrants , and 0.3 million shares of common stock upon conversion of series c convertible preferred stock . 46 liquidity and capital resources as of december 31 , 2019 , we had $ 10,195,292 in cash and cash equivalents . net cash used in operating activities for the year ended december 31 , 2019 was $ 13,267,500 , compared to $ 13,199,013 for the year ended december 31 , 2018 . our use of cash was primarily a result of the net loss of $ 16,414,159 for the year ended december 31 , 2019 , adjusted for items mainly related to stock-based compensation of $ 884,943 , release of clinical trial funding commitment of $ 703,327 , and depreciation and amortization of $ 494,232 . the changes in our operating assets and liabilities consisted primarily of higher accounts payable and accrued expenses . at our current and anticipated levels of operating losses , we expect to continue to incur an operating cash outflow for the next several years . as of december 31 , 2019 and 2018 , we had working capital of $ 6,571,985 and $ 9,841,947 , respectively . the decrease in working capital is primarily due to the decrease in cash and cash equivalents and an increase in accrued liabilities . net cash ( used ) /provided by investing activities was $ ( 67,622 ) and $ 22,842 for the years ended december 31 , 2019 and 2018 , respectively . investing activities during the year ended december 31 , 2019 consisted primarily of the purchase of capital equipment of $ 67,622 , while investing activities during the year ended december 31 , 2018 consisted primarily of cash provided by disposal of capital equipment of $ 27,942 . story_separator_special_tag style= `` line-height:120 % ; text-indent:48px ; font-size:10pt ; `` > on may 10 , 2019 , we entered into a securities purchase agreement with lpc , gross proceeds were approximately $ 1.5 million . the may 2019 securities purchase agreement consisted of ( i ) 458,015 shares of common stock ( including pre-funded warrants ) at a purchase price of $ 3.275 per share and ( ii ) 458,015 series d warrants with an exercise price of $ 3.15 per share , expiring on november 12 , 2024. none of the series d warrants have been exercised as of february 20 , 2020. on august 20 , 2019 , we entered into a securities purchase agreement with lpc , gross proceeds were approximately $ 1.5 million . the august 2019 securities purchase agreement consisted of ( i ) 727,802 shares of common stock ( including pre-funded warrants ) at a purchase price of $ 2.061 per share and ( ii ) 727,802 series f warrants with an exercise price of $ 1.936 per share , expiring on february 24 , 2025. none of the series f warrants have been exercised as of february 20 , 2020. on october 30 , 2019 , we closed a private placement with certain institutional investors for gross proceeds of approximately $ 5.0 million . we sold an aggregate of ( i ) 2,756,340 shares of common stock ( including pre-funded warrants ) at a purchase price of $ 1.814 per share , ( ii ) 2,756,340 series g warrants with an exercise price of $ 1.56 per share , expiring on april 30 , 2025 , ( iii ) 2,756,340 series h warrants with an exercise price of $ 1.56 per share , expiring on april 30 , 2021 , and ( iv ) 206,726 placement agent warrants at an exercise price of $ 2.2675 per share , expiring on april 30 , 2025. none of the series g or placement agent warrants have been exercised as of february 20 , 2020. we received net proceeds of approximately $ 1.5 million from the exercise of 1,005,072 series h warrants on january 27 , 2020. nasdaq notice on september 5 , 2017 , we received a written notice from nasdaq notifying us that we were not in compliance with nasdaq listing rule 5550 ( a ) ( 2 ) for continued listing on the nasdaq capital market , as the minimum bid price of our common stock had been below $ 1.00 per share for 30 consecutive business days . the notice had no immediate effect on the listing of our common stock , and our common stock continued to trade on the nasdaq capital market under the symbol “ trov ” . in accordance with nasdaq listing rule 5810 ( c ) ( 3 ) ( a ) , we had until march 5 , 2018 , to regain compliance with the minimum bid price requirement . on march 6 , 2018 , nasdaq informed us that we were eligible for an additional 180 calendar day period until september 4 , 2018 to regain compliance with the minimum $ 1.00 bid price per share requirement . to regain compliance ,

